Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALKS |
---|---|---|
09:32 ET | 4620 | 24.205 |
09:34 ET | 1150 | 24.25 |
09:36 ET | 5212 | 24.22 |
09:39 ET | 500 | 24.205 |
09:41 ET | 1009 | 24.215 |
09:43 ET | 1692 | 24.25 |
09:45 ET | 366 | 24.2 |
09:48 ET | 1112 | 24.27 |
09:50 ET | 1114 | 24.26 |
09:52 ET | 500 | 24.26 |
09:54 ET | 1717 | 24.26 |
09:56 ET | 500 | 24.24 |
09:57 ET | 2145 | 24.27 |
09:59 ET | 400 | 24.23 |
10:01 ET | 751 | 24.2 |
10:03 ET | 2900 | 24.2101 |
10:06 ET | 6500 | 24.29 |
10:08 ET | 1726 | 24.27 |
10:10 ET | 806 | 24.23 |
10:12 ET | 4125 | 24.23 |
10:14 ET | 58206 | 24.22 |
10:15 ET | 42257 | 24.19 |
10:17 ET | 2670 | 24.22 |
10:21 ET | 4478 | 24.19 |
10:24 ET | 1832 | 24.21 |
10:26 ET | 3260 | 24.205 |
10:28 ET | 9259 | 24.19 |
10:30 ET | 3884 | 24.19 |
10:32 ET | 3658 | 24.165 |
10:33 ET | 100 | 24.17 |
10:35 ET | 1176 | 24.18 |
10:37 ET | 2460 | 24.16 |
10:39 ET | 400 | 24.18 |
10:42 ET | 4000 | 24.16 |
10:44 ET | 900 | 24.15 |
10:46 ET | 1178 | 24.1202 |
10:48 ET | 2175 | 24.13 |
10:50 ET | 1400 | 24.14 |
10:53 ET | 1288 | 24.13 |
10:55 ET | 701 | 24.14 |
10:57 ET | 500 | 24.145 |
11:00 ET | 1600 | 24.155 |
11:02 ET | 2450 | 24.155 |
11:04 ET | 1750 | 24.16 |
11:06 ET | 1294 | 24.16 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Alkermes Plc | 4.1B | 6.9x | --- |
Exelixis Inc | 6.1B | 32.5x | -21.77% |
PTC Therapeutics Inc | 2.5B | -5.1x | --- |
P3 Health Partners Inc | 191.1M | -1.0x | --- |
Novavax Inc | 1.8B | -4.4x | --- |
Halozyme Therapeutics Inc | 5.7B | 18.5x | --- |
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.1B |
---|---|
Revenue (TTM) | $1.7B |
Shares Outstanding | 169.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.45 |
EPS | $3.50 |
Book Value | $7.20 |
P/E Ratio | 6.9x |
Price/Sales (TTM) | 2.4 |
Price/Cash Flow (TTM) | 6.2x |
Operating Margin | 29.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.